Differences

This shows you the differences between two versions of the page.

--- home:pathogenesis:microbiota:interaction [03.20.2020] – [Viruses] sallieq
+++ home:pathogenesis:microbiota:interaction [03.28.2020] – [Viruses] sallieq
@@ Line 38: / Line 38: @@
 [[http://www.koreabiomed.com/news/articleView.html?idxno=7718|Fewer new cases 20/3/2020 (Korea) ]]
+current evidence(({{pubmed>long:    32096567}}))
+breakthrough(({{pubmed>long:    32074550}}))
+chloroquine (({{pubmed>long:    32147496}}))
+ neuroinvasive potential(({{pubmed>long:    32104915}}))
+Unique epidemiological and clinical features(({{pubmed>long:    32134116}}))
+What we know so far(({{pubmed>long:    32139372}}))
+Presumed Asymptomatic Carrier Transmission(({{pubmed>long:    32083643}}))
+Discovering drugs(({{pubmed>long:    32147628}}))
+[[https://www.mediterranee-infection.com/wp-content/uploads/2020/03/Hydroxychloroquine_final_DOI_IJAA.pdf|small sample size survey shows hydroxychloroquine treatment is significantly associated with viral load reduction in COVID-19 patients, effect is reinforced by azithromycin.]]
+February 2020 The multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion. It recommended chloroquine phosphate tablet, 500mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of novel coronavirus pneumonia and without contraindications to chloroquine. (({{pubmed>long:32075365}}))
 ==== Bacteria ====

home/pathogenesis/microbiota/interaction.txt · Last modified: 09.14.2022 by 127.0.0.1